SynthesisBMC pulmonary medicine2025
Efficacy evaluation of allergen-specific immunotherapy in children with asthma: a systematic review and meta-analysis.
Synthesis in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Differential Metabolites Before and After Allergen Specific Immunotherapy in Children with Allergic Asthma.Journal of asthma and allergy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAsthma is the most common chronic respiratory disease in children. Although conventional treatments such as inhaled corticosteroids and long-acting β2-receptor agonists can effectively control symptoms, some children still face the problem of frequent attacks and drug side effects. As a potential etiological treatment, allergen-specific immunotherapy aims to induce immune tolerance by gradually increasing exposure to specific allergens, thereby relieving asthma symptoms in the long term. This meta-analysis aims to synthesize the existing high-quality evidence and systematically review the efficacy of allergen-specific immunotherapy for childhood asthma.
methodsWe performed literature search, screening, and data extraction according to the Cochrane Collaboration guidelines. A computerized search of PubMed, Embase, Web of Science, Cochrane Central, and CNKI databases was performed, and 10 randomized controlled clinical trials (RCTs) were included. Two independent reviewers screened the literature, extracted data, and assessed the risk of bias according to predefined criteria. The main outcome measures included TASS, TMS, VAS scores, and FEV1%.
resultsA total of 10 RCT studies were included, and all met the inclusion criteria. Meta-analysis results showed that allergen-specific immunotherapy showed a positive effect in improving the symptoms of childhood asthma and reducing the need for medication. Specifically, immunotherapy significantly reduced the total asthma symptom score (TASS, SMD=-1.05, 95% CI [-2.09; -0.01]) and total medication score (TMS, SMD=-1.32, 95%CI [-2.21; -0.43]). However, no significant difference was found in VAS score and FEV1% (SMD=-1.77, 95% CI [-3.76;0.22]; SMD = 0.51, 95% CI [-0.38;1.40]). All indicators had high heterogeneity.
conclusionAllergen-specific immunotherapy showed a positive effect in improving the symptoms of childhood asthma and reducing the need for medication, but there was significant heterogeneity among different studies. More high-quality RCTs are needed in the future to further explore the safety and long-term efficacy of immunotherapy to optimize its application in the management of childhood asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.